Prosecution Insights
Last updated: October 02, 2026

Tau Medical Inc.

Technology area: Medical Devices & Mechanical Engineering

5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Tau Medical Inc. has 4 pending office actions in the Medical Devices & Mechanical Engineering technology area. These actions are distributed across 4 distinct examiners and 3 distinct art units. This distribution indicates that each pending matter is being handled by a different examiner, requiring a broad approach to managing individual examiner preferences. The presence of 3 art units for the 4 actions suggests that the company's medical device innovations are categorized into a few closely related technical sub-groups.

Abigail Marie Bock is the busiest examiner for the portfolio, currently managing 1 pending office action. With the examiners spread across the different art units, the company must address a variety of examiner styles while operating within a relatively small number of technical departments. This requires tailoring prosecution strategies to the specific nuances of each of the 4 examiners involved. Because each examiner is responsible for only 1 pending action, the workload is evenly distributed. Abigail Marie Bock is one of the individuals whose specific feedback must be addressed to advance the company's interests.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

5
Total Pending OAs
4
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (40%)
2
Medium (40%)
1
Easy (20%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (20%)
§103 only2 (40%)
Double-patenting only1 (20%)
Multi-statute (no §101)1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

0
Life Sciences
0% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
4
Mechanical / Eng
80% of docket
1
Business / Other
20% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BOCK, ABIGAIL MARIE 1 91.0% +7.3%
TYSON, MELANIE RUANO 1 68.4% +18.9%
LE, KHOA TAN 1 78.0% +38.2%
GANESAN, SUBA 1 73.8% +13.4%
ZHANG, LEI 1 15.4% +100.0%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18977761 RF ABLATION CATHETER FOR SEPTAL REDUCTION THERAPY HAVING COOLING EFFECT BOCK, ABIGAIL MARIE —

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18074473 DEVICES AND METHODS FOR TREATING LUNG TUMORS ZHANG, LEI 30d overdue
18035509 TRANSCATHETER DEVICE FOR TREATING TRICUSPID VALVE REGURGITATION GANESAN, SUBA 10d overdue

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18074473 DEVICES AND METHODS FOR TREATING LUNG TUMORS ZHANG, LEI 30d overdue
18568537 ACCESS INTO INTERVENTRICULAR SEPTUM USING A PUNCTURE CATHETER DEVICE LE, KHOA TAN 17d overdue
18035509 TRANSCATHETER DEVICE FOR TREATING TRICUSPID VALVE REGURGITATION GANESAN, SUBA 10d overdue
18392344 TRANSCATHETER DEVICE FOR TREATING TRICUSPID VALVE REGURGITATION TYSON, MELANIE RUANO —

Top Art Units

Art UnitApps
3774 2
3771 1
3798 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18977761 RF ABLATION CATHETER FOR SEPTAL REDUCTION THERAPY HAVING COOLING EFFECT BOCK, ABIGAIL MARIE — DP Non-Final OA — Pending Dec 11, 2024
18392344 TRANSCATHETER DEVICE FOR TREATING TRICUSPID VALVE REGURGITATION TYSON, MELANIE RUANO 3774 §103 Non-Final OA — Pending Dec 21, 2023
18568537 ACCESS INTO INTERVENTRICULAR SEPTUM USING A PUNCTURE CATHETER DEVICE LE, KHOA TAN 3771 §103 Non-Final OA 17d overdue Pending Dec 08, 2023
18035509 TRANSCATHETER DEVICE FOR TREATING TRICUSPID VALVE REGURGITATION GANESAN, SUBA 3774 §101§103 Final Rejection 10d overdue Pending May 04, 2023
18074473 DEVICES AND METHODS FOR TREATING LUNG TUMORS ZHANG, LEI 3798 §102§103§112 Non-Final OA 30d overdue Pending Dec 03, 2022

Managing Tau Medical Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month